IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment.
A group of 9 Mexican lepromatous leprosy patients was studied at the beginning of a type II reaction (erythema nodosum leprosum, ENL) and after 1 or 2 months of thalidomide treatment. ENL patients at the onset of the reaction had slightly higher amounts of anti-Mycobacterium leprae IgG1 and IgG2 antibodies, compared to similar lepromatous patients that did not develop ENL. Neither these antibody levels nor IgM and the other IgG subclasses were importantly modified after thalidomide treatment. Serum TNF was significantly higher in the patients that developed ENL compared to those that did not develop the reaction. TNF levels were slightly decreased after 1 month of thalidomide treatment and significantly decreased after 2 months of treatment. Serum IFN-gamma was significantly lower in patients at the onset of ENL and was increased after 1 and 2 months of thalidomide treatment.
Partida-Sanchez
S
S
Department of Immunology, National School of Biological Sciences, Mexico City, Mexico.
Favila-Castillo
L
L
Pedraza-Sanchez
S
S
Gomez-Melgar
M
M
Saul
A
A
Estrada-Parra
S
S
Estrada-Garcia
I
I
D000293:Adolescent; D000328:Adult; D000368:Aged; D000907:Antibodies, Bacterial / Q000097:blood / Q000145:classification*; D003627:Data Interpretation, Statistical; D004893:Erythema Nodosum / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood* / Q000145:classification*; D007075:Immunoglobulin M / Q000097:blood / Q000145:classification; D007371:Interferon-gamma / Q000097:blood / Q000378:metabolism*; D007917:Leprostatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015439:Leprosy, Borderline / Q000097:blood / Q000188:drug therapy; D015440:Leprosy, Lepromatous / Q000188:drug therapy* / Q000378:metabolism; D015441:Leprosy, Tuberculoid / Q000097:blood / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009166:Mycobacterium leprae / Q000276:immunology; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007917:Leprostatic Agents; D014409:Tumor Necrosis Factor-alpha; D013792:Thalidomide; D007371:Interferon-gamma